Raph L Hamers
Impact in
- Infectious Diseases top 0.2%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Tuberculosis Research and Epidemiology
- Virology top 1%
- HIV Research and Treatment
Papers in
-
- HIV/AIDS drug development and treatment 67
- HIV/AIDS Research and Interventions 26
- COVID-19 Clinical Research Studies 20
- SARS-CoV-2 and COVID-19 Research 8
-
- Antibiotic Use and Resistance 28
- Co-authors
- Tobias F. Rinke de Wit (52 shared papers)Cissy M Kityo (27 shared papers)Kim Sigaloff (26 shared papers)Wendy Susan Stevens (19 shared papers)Margaret Siwale (20 shared papers)Kishor N. Mandaliya (19 shared papers)Carole Lorraine Wallis (10 shared papers)Rob Schuurman (6 shared papers)
- Journals
- The Lancet Infectious Diseases (15 papers)Wellcome Open Research (14 papers)AIDS (10 papers)Journal of Antimicrobial Chemotherapy (9 papers)Clinical Infectious Diseases (7 papers)
- Partner nations
- United KingdomNetherlandsIndonesia
In The Last Decade
Raph L Hamers
169 papers receiving 6.2k citations
Raph L Hamers's Hit Papers
Peers
Comparison fields: 5 of 131
- Infectious Diseases 4.7k
- Virology 656
- Applied Microbiology and Biotechnology 282
- Molecular Medicine 106
- Internal Medicine 36
Countries citing papers authored by Raph L Hamers
This map shows the geographic impact of Raph L Hamers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raph L Hamers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raph L Hamers more than expected).
Fields of papers citing papers by Raph L Hamers
This network shows the impact of papers produced by Raph L Hamers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raph L Hamers. The network helps show where Raph L Hamers may publish in the future.
Co-authors
The 25 scholars most cited alongside Raph L Hamers, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 179 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis Hit paper breakdown → | 2017 | 327 |
| 2 | Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis Hit paper breakdown → | 2018 | 321 |
| 3 | 2012 | 306 | |
| 4 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 5 | 2011 | 253 | |
| 6 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 7 | 2016 | 222 | |
| 8 | 2021 | 213 | |
| 9 | 2015 | 194 | |
| 10 | 2011 | 170 | |
| 11 | 2011 | 165 | |
| 12 | 2021 | 164 | |
| 13 | 2012 | 149 | |
| 14 | WHO global research priorities for antimicrobial resistance in human health Hit paper breakdown → | 2024 | 126 |
| 15 | 2021 | 117 | |
| 16 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 17 | 2016 | 83 | |
| 18 | 2009 | 75 | |
| 19 | 2015 | 72 | |
| 20 | 2018 | 72 |
About Raph L Hamers
Raph L Hamers is a scholar working on Infectious Diseases, Applied Microbiology and Biotechnology, Virology, Molecular Medicine and Surgery, having authored 179 papers that have together received 6.4k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (67 papers), Antibiotic Use and Resistance (28 papers), HIV/AIDS Research and Interventions (26 papers), COVID-19 Clinical Research Studies (20 papers), Infectious Diseases and Tuberculosis (14 papers), HIV Research and Treatment (9 papers), SARS-CoV-2 and COVID-19 Research (8 papers) and Antibiotic Resistance in Bacteria (7 papers). The work is most often cited by research in Infectious Diseases (4.7k citations), Virology (656 citations), Applied Microbiology and Biotechnology (282 citations), Molecular Medicine (106 citations) and Internal Medicine (36 citations). Raph L Hamers has collaborated with scholars based in United Kingdom, Netherlands and Indonesia. Frequent co-authors include Tobias F. Rinke de Wit, Cissy M Kityo, Kim Sigaloff, Wendy Susan Stevens, Margaret Siwale, Kishor N. Mandaliya, Carole Lorraine Wallis, Rob Schuurman, Michèle van Vugt and Maureen Wellington. Their work appears in journals such as The Lancet Infectious Diseases, Wellcome Open Research, AIDS, Journal of Antimicrobial Chemotherapy and Clinical Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.